Physician profile
Lindita Vinca
NPI 1396093993
$427,308.31
in general payments reported to CMS, 2019-2025
32 companies · $197K in 2025
The $197K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,013 · 2022: $7,106 · 2023: $73K · 2024: $143K · 2025: $197K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $265K · Travel and Lodging: $73K · Consulting Fee: $36K · Food and Beverage: $28K · Honoraria: $11K · Education: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $265,103.37 |
| Travel and Lodging | $72,822.46 |
| Consulting Fee | $36,088.50 |
| Food and Beverage | $27,822.17 |
| Honoraria | $10,850.00 |
| Education | $502.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $269,138.39 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $35,159.44 | 2021-2025 | |
| Abbvie INC. | $31,387.77 | 2021-2025 | |
| Incyte Corporation | $17,441.82 | 2021-2025 | Opzelura |
| Organon LLC | $14,995.52 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $14,762.23 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $10,210.29 | 2023-2025 | Zoryve |
| Pfizer INC. | $7,316.23 | 2021-2025 | |
| Galderma Laboratories, L.P. | $6,849.36 | 2021-2025 | Nemluvio, Aklief |
| Medimetriks Pharmaceuticals, INC. | $5,238.13 | 2021-2025 | Clindacin Etz, Neo-Synalar, Sumadan Wash |
| Dermavant Sciences, INC. | $2,460.95 | 2022-2024 | Vtama |
| Leo Pharma INC. | $1,590.47 | 2021-2025 | Adbry, Anzupgo |
| Almirall LLC | $1,475.00 | 2021-2025 | Seysara, Klisyri |
| Novartis Pharmaceuticals Corporation | $1,438.06 | 2023-2025 | |
| Eli Lilly and Company | $1,389.36 | 2024 | Olumiant, Taltz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,184.43 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $1,106.28 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $787.22 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Amgen INC. | $707.86 | 2021-2025 | Otezla |
| Ucb, INC. | $468.86 | 2023-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $446.99 | 2021-2025 | Cabtreo |
| Epi Health, LLC | $320.77 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $319.42 | 2021 | |
| Journey Medical Corporation | $307.27 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $295.05 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.29 | 2022-2025 | Spevigo |
| Janssen Scientific Affairs, LLC | $120.98 | 2022 | |
| Botanix Sb INC | $112.58 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $46.96 | 2023-2024 | Ycanth |
| Lnhc, INC | $20.61 | 2025 | Zelsuvmi |
| Paratek Pharmaceuticals, INC. | $20.09 | 2022 | |
| Dermira, INC. | $14.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindita Vinca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.